US Biosimilars: Busting Blockbusters Or Managing Obsolescence?

As a new generation of biosimilars challenge some of pharma’s biggest-selling products, this In Vivo analysis looks at how the originator blockbuster might fare in the face of competition. Experience in Europe, which predates that in the US by about a decade, provides a number of crucial pointers to outcomes and defensive strategies.